• 1
  • 2
pe pagina
  • 150.00 lei

     Editia a opta a manualului Clasificarea TNM a Tumorilor Maligne pune la dispozitie ultimele consensuri si standarde internationale utilizate pentru a descrie si a caracteriza corespunzator stadiile maladiilor oncologice. Editat in afiliere cu Uniunea pentru Controlul International al Cancerului (UICC), acest „ghid de buzunar”, autorizat si unanim recunoscut, contine importante clasificari reactualizate pentru localizari tumorale specifice, de catre medicii oncologi si profesionistii din domeniul sanatatii, implicati in managementul terapeutic al pacientilor afectati de aceste boli, trebuie sa țina cont pentru stadializarea, clasificarea, prognosticul si atitudinea terapeutica optima privind aceste maladii.

    •       In acest „ghid de buzunar” omologat international, se gasesc ultimele noutati privind atat stadializarea carcinoamelor de cap si gat, a carcinoamelor tiroidiene, esofagiene, gastrice, colorectale, pulmonare, pleurale, a tumorilor cutanate, ovariene, de prostata, ale glandului si ale cortexului suprarenal, cat si stadializarea tumorilor neuroendocrine, a sarcoamelor osoase si de tesuturi moi, dispuse intr‑o maniera simpla si precisa, pe regiuni anatomice.

    •       In această editie, sunt introduse noi clasificari pentru carcinoamele orofaringiene p16‑pozitive, tumorile timice, tumorile neuroendocrine cu origine pancreatica, pentru sarcoame ale coloanei vertebrale si ale pelvisului, sarcoame de tesuturi moi ale capului si ale gatului, toracice, tumori cu originea in viscerele abdominale si in spatiul retroperitoneal.

    •        Pentru a inlesni colectarea datelor necesare clasificarii si monitorizarii maladiilor oncologice in țarile cu venituri mici si mijlocii, au fost adaugate noi sectiuni in capitolul Schema Esentială TNM in ceea ce priveste tumorile de colon, rect, cele ale glandei mamare si ale colului uterin si carcinoamele prostatei, dar si stadializari simplificate pentru tumorile pediatrice.

    •       Structura limpede si prelucrata pe baza unor tipare usor de utilizat a capitolelor care cuprind subdiviziuni anatomice, retele de drenaj ganglionar, clasificarea clinică si patologică TNM, gradul histopatologic, gruparea pe stadii si, mai nou, gruparea in functie de prognostic (acolo unde este relevant) permite accesul fara intarziere la informatii‑cheie.

    Un format reactualizat si cromatica folosita rafineaza si sporeste gradul de întrebuintare a acestei resurse indispensabile pentru toți specialistii din medicina, oncologi, radioterapeuti, chirurgi, patologi, asistenti medicali, persoane abilitate sa ofere îngrijiri paliative, pentru centre internaționale dedicate terapiilor cu viza oncologica, organizații guvernamentale si non‑guvernamentale implicate activ in lupta contra cancerului.

    DESPRE UICC

    „Unim comunitatea afectata de maladiile oncologice pentru a reduce problema globala pe care acestea o reprezinta, promovam echitatea si integram controlul neoplaziilor in agenda universala pentru sanatate si dezvoltare”.

     

  • Pocket Radiation Oncology (Pocket Notebook)
    by Tang
    La comanda in aproximativ 4 saptamani
    18500lei 175.00 lei

    Pocket Radiation Oncology is a practical, high-yield reference offering current, evidence-based practices and expert guidance from physicians at the world-renowned MD Anderson Cancer Center. Featuring an easy-to-use, loose-leaf format, it serves as a concise clinical companion and board study guide for medical students, residents, and attending physicians in radiation oncology. Follows the popular Pocket Notebook format, featuring bulleted lists, tables, diagrams, and algorithms that make essential facts easy to find and retain. Emphasizes key literature and clinical trials in every section. Provides solutions to day-to-day management decisions in radiation oncology, including management of radiation induced symptoms, radiation physics, radiation biology, pediatrics, and radiation emergencies.

    ·  Contents

    ·  RADIATION ONCOLOGY PRINCIPLES

    ·  Radiation Biology

    ·  Radiation Physics

    ·  Imaging and Radiology

    ·  Chemotherapy and Immunotherapy

    ·  Clinical Statistics

    ·  SPECIAL RADIATION TECHNIQUES

    ·  Brachytherapy

    ·  Proton Therapy

    ·  Oligometastatic Disease

    ·  Stereotactic Body Radiation Therapy

    ·  Stereotactic CNS Radiosurgery

    ·  CENTRAL NERVOUS SYSTEM

    ·  Low-Grade Gliomas

    ·  High-Grade Gliomas

    ·  Meningioma

    ·  Benign CNS

    ·  Pituitary Adenoma and Craniopharyngioma

    ·  PEDIATRICS

    ·  Medulloblastoma

    ·  Ependymoma

    ·  Intracranial Germ Cell Tumor

    ·  Wilms Tumor

    ·  Neuroblastoma

    ·  Ewing Sarcoma

    ·  Rhabdomyosarcoma

    ·  Osteosarcoma/Retinoblastoma/Brainstem Glioma

    ·  Late Effects

    ·  HEAD & NECK

    ·  Oral Cavity

    ·  Oropharynx

    ·  Sinonasal and Nasopharynx

    ·  Larynx and Hypopharynx

    ·  Salivary Gland Neoplasms

    ·  Thyroid Cancer

    ·  Unknown Head and Neck Primary

    ·  THORACIC

    ·  Early-Stage NSCLC

    ·  Stage III NSCLC

    ·  Small Cell Lung Cancer

    ·  Thymoma and Thymic Carcinoma

    ·  Mesothelioma

    ·  Esophageal Cancer

    ·  GASTROINTESTINAL

    ·  Colorectal Cancer

    ·  Anal Cancer

    ·  Pancreatic Cancer

    ·  Gastric Cancer

    ·  Hepatobiliary Cancer

    ·  BREAST

    ·  General Breast Cancer

    ·  Ductal Carcinoma In Situ (DCIS)

    ·  Early-Stage Breast Cancer (ESBC)

    ·  Locally Advanced Breast Cancer (LABC)

    ·  Inflammatory/Recurrent Breast Cancer

    ·  GENITOURINARY

    ·  Prostate Cancer (Definitive)

    ·  Prostate Cancer (Adjuvant/Salvage)

    ·  Bladder Cancer

    ·  Testicular Cancer

    ·  Penile Cancer

    ·  GYNECOLOGIC

    ·  Cervical Cancer

    ·  Endometrial Cancer

    ·  Vaginal Cancer

    ·  Vulvar Cancer

    ·  Ovarian Cancer

    ·  SKIN/SARCOMA

    ·  Soft Tissue Sarcoma

    ·  Melanoma

    ·  Non-melanoma Skin Cancer

    ·  Merkel Cell Carcinoma

    ·  LYMPHOMA

    ·  Hodgkin Lymphoma

    ·  Diffuse Large B-Cell Lymphoma

    ·  Miscellaneous Hematologic Malignancies

    ·  RADIATION EMERGENCIES, BENIGN DISEASE, AND PALLIATION

    ·  Brain Metastases

    ·  Spine Metastases

    ·  Non-spine Bone Metastases

    ·  Radiation Emergencies

    ·  Benign Disease: Non-neural

    ·  Clinical Setup


  • 21000lei 185.00 lei

    In curand si in limba romana!

    TNM Classification of Malignant Tumours eighth edition provides the latest, internationally agreed-upon standards to describe and categorize cancer stage. 
    • Published in affiliation with the Union for International Cancer Control (UICC)
    • Arranged by anatomical region, this authoritative pocket sized guide contains many important updated organ-specific classifications 
    • There are new classifications for p16 positive oropharyngeal carcinomas, carcinomas of the thymus, neuroendocrine tumours of the pancreas, and sarcomas 
    • To facilitate the collection of stage data for cancer surveillance in low and middle income countries there are new sections on Essential TNM and Paediatric Cancer Stage
    • New colour presentation

  • 25400lei 204.00 lei

    Concise, portable, and packed with essential information, Manual of Clinical Oncology is an indispensable resource for understanding basic science, clinical findings, and available technology as they relate to the diagnosis and management patients with cancer.  The practical format provides high-yield content useful for participating in rounds ad making diagnostic and therapeutic decisions at the bedside.  Edited by Dr. Bartosz Chmielowski  and Dr. Mary Territo, both from UCLA School of Medicine, this eighth edition carries on the tradition of excellence set forth by longtime editor Dr. Dennis Casciato.

    Key Features:

    • Incorporates recent major achievements in immunotherapies, biologics, and targeted therapies.
    • Features new chapters on the biology of cancer, immunotherapy, and cancer survivorship.
    • Contains numerous diagnostic and treatment algorithms, as well as content on complications, for assistance with clinical decision making.
    • Includes helpful appendices such as a glossary of cytogenetic nomenclature and combination chemotherapy regimens.

    Your book purchase includes a complimentary download of the enhanced eBook for iOS, Android, PC & Mac. Take advantage of these practical features that will improve your eBook experience:

    • The ability to download the eBook on multiple devices at one time — providing a seamless reading experience online or offline
    • Powerful search tools and smart navigation cross-links that allow you to search within this book, or across your entire library of VitalSource eBooks
    • Multiple viewing options that enable you to scale images and text to any size without losing page clarity as well as responsive design
    • The ability to highlight text and add notes with one click

  • 215.00 lei

    Now fully revised and in its fourth edition, the Oxford Handbook of Oncology has been the essential go-to guide for students and practitioners in oncology for over a decade. The scientific basis and diagnosis of cancers is covered, as well as drugs, biomarkers, and the presentation and psychosocial aspects of oncology. Concise, practical, and comprehensive, there is no better companion for both common conditions and challenging emergencies. The field of oncology has surged forward since the last edition was published and the Oxford Handbook of Oncology has been fully revised and updated to reflect these recent advances so you can be sure that the vital information you need is in your hands. This handbook incorporates changes such as the understanding of the science of cancer, novel therapies in breast, lung, renal, and melanoma, molecular sub-classification of common solid cancers, personalized therapy approaches, new agents in hard to treat cancers, the benefits of new technologies in radiotherapy, and the emerging data on the importance of the immune response. Written by experts in the field to ensure that it is grounded in real life clinical practice, this handbook provides a concise guide to all aspects of oncology for all students, nurses, and junior faculty responsible for the care of cancer patients, while also providing further reading and highlighting areas of controversy for those who need a more detailed understanding.

  • Molecular Biology of Cancer
    La comanda in aproximativ 4 saptamani
    24800lei 225.00 lei

    Lauren Pecorino

    • Provides an engaging and manageable route into the complex subject of cancer biology
    • Describes the theoretical basis of cancer biology and shows how this theory is applied to develop new cancer therapies, giving students a clear appreciation of how theoretical knowledge can be translated into therapeutic strategies
    • Draws on the latest research in this dynamic field but presents it in a manner readily accessible to the student

    New to this Edition:

    • New full colour diagrams help students to visualize the key concepts explained in the text more effectively
    • Expanded coverage of tumour immunology and immunotherapy, discussing tumour suppression and tumour promotion mechanisms of the immune system and the exciting new applications of this knowledge towards developing cancer immunotherapies

  • Paediatric Palliative Medicine
    La comanda in aproximativ 4 saptamani
    250.00 lei

    Looking after children with life-limiting conditions is very difficult for both parents and health care professionals. This second edition of Paediatric Palliative Medicine is full of easily-accessible, detailed information , and covers all aspects of the care of children with life-limiting illnesses. It is designed to equip clinicians with the knowledge, and its evidence base, to improve clinical care.

    Using the bestselling Oxford Specialist Handbook format to deliver practical and concise information, this handbook facilitates bedside delivery of effective palliative medicine to children. It includes a quick reference drug formulary and detailed information on medical conditions and symptom control. There are also specific management plans to guide professionals, whether the child is in their own home, in a hospital, or a hospice.

    Many children with long term conditions have symptoms which need management, and the principles of palliative care for children need to be known by all who are involved in their care. The unique significance of this handbook is its capacity to guide professionals who have not trained or had experience of caring for the dying child, as well as for students and trainees interested in paediatric palliative care.

    Children's palliative medicine encompasses symptom control but is not limited to it. This handbook also provides a wealth of information on the philosophy and models that support delivery of palliative medicine to children, as well as the learning and coping skills required in palliative care.

    Fully updated with an expanded formulary and a new chapter on the intensive care unit, this new edition continues to be the authoritative reference tool in paediatric palliative care.

  • 260.00 lei

    The new edition of this book is a complete guide to the diagnosis and management of head and neck cancers. Divided into seven sections, the text covers thyroid, salivary glands and parapharyngeal tumours, neck, paranasal sinuses, oral cavity and oropharynx, larynx, hypopharynx and nasopharynx, with a final section on general topics. Each topic includes discussion on pathology, imaging, and medical and surgical management. The second edition has been fully revised to provide the latest advances in the field, and includes new chapters on parathyroid tumours, infratemporal fossa, temporal bone tumours, facial nerve tumours, tracheostomy, and skin cancers. Recent changes in the American Joint Cancer Committee (AJCC) 8th Edition staging system have been incorporated. More than 300 photographs, illustrations and tables further enhance the comprehensive text. Key points Comprehensive guide to diagnosis and management of head and neck cancers Fully revised, second edition with many new topics included Covers recent changes in the American Joint Cancer Committee (AJCC) 8th Edition staging system Previous edition (9789351527916) published in 2015

  • 29100lei 270.00 lei

    This book comprehensively and thoroughly reviews the current literature regarding the impact of health disparities and socioeconomic factors on allergic diseases outcomes: such as food allergies and anaphylaxis. The morbidity associated with these conditions is significantly higher in under-privileged populations around the world, including groups who have experienced greater social or economic obstacles to health based on racial, socioeconomic, gender, geographic location. Health Disparities in Allergic Diseases presents evidence and reviews studies from both developed and developing countries that witness health disparities in allergic disease. Concise in format, Health Disparities in Allergic Diseases: An Evidence-Based Look at Causes, Conditions, and Outcomes is made up of 11 expertly written chapters and divided into two parts. It begins with an introductory on global health through an analysis of the theoretical framework of epidemiologic transition. Subsequent chapters then review the socioeconomic and racial variables in treating allergic diseases using a multifactorial approach. Part II discusses disparities in allergic conditions, including asthma health, rhinitis and rhinosinusitis, food allergy, and atopic dermatitis. The book concludes with an exploration of potential strategies to providing solutions for asthmatic impoverished populations. Health Disparities in Allergic Diseases is a practical resource that can be used by researchers and clinicians in the field of allergy who are interested in learning about health related disparities in the context of allergic conditions or who seek solutions for this important issue.

    ·  Part I. Introductory Chapters

    ·  1. Global Health: Reimagining Perspectives

    ·  2. Allergic Diseases in the Developing World: An Emerging Problem or an Overseen Issue?

    ·  3. Racial and Ethnic Disparity in Allergic Diseases in the United States: Example of a Large Country with a Diverse Population

    ·  4. Disparity in Access to Care and Its Impact on Diagnosis and Outcomes of Allergic Diseases

    ·  Part II. Disparity on Allergic Conditions by Disease

    ·  5. Disparity in Rhinitis and Rhinosinusitis

    ·  6. Disparities in Food Allergy

    ·  7. Asthma Health Disparities

    ·  8. Disparity in Atopic Dermatitis

    ·  Part III. Providing Solutions

    ·  9. School-Based Educational Programs to Improve the Knowledge and Outcome in Allergic Conditions

    ·  10. Providing Feasible Solutions for an Asthmatic Impoverished Population

    ·  11. Global and National Networks and Their Role in Fighting Disparity in Allergic Diseases


  • 270.00 lei

     

     

    Description:

    Completely revised and updated for 2020, the Physicians' Cancer Chemotherapy Drug Manual is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalogue of over 100 drugs and commonly used drug regimens-both on- and off-label-for the treatment of all the major cancers.

    Key Features:

    * Addition of 17 new agents, 2 biosimilars, and several new supplemental indications that have all been approved by the FDA within the past year

    * Updated new indications for previously approved agents

    * Indications, drug doses and schedules, toxicities, and special considerations for each agent expanded and revised

    * A specific chapter focused on antiemetic treatment regimens for both acute and delayed nausea/vomiting

     * Diagrams of drug structures and pathways for many of the agents

    * A comprehensive discussion of clinical pharmacology, special considerations, indications, and dosages

     * Covers toxicity and drug-drug interactions

     * A section on chemotherapy regimens for all major cancers * Provides an overview of the basic principles of cancer drug therapy.

     

    Contents:

     

    CHAPTER 1 Principles of Cancer Chemotherapy

    1

       

    CHAPTER 2 Chemotherapeutic and Biologic Drugs

    5

       

    CHAPTER 3 Guidelines for Chemotherapy and Dosing Modifications

    537

       

    CHAPTER 4 Common Chemotherapy Regimens in Clinical Practice

    565

       

    CHAPTER 5 Antiemetic Agents for the Treatment of ChemotherapyInduced Nausea and Vomiting

    725

       

     

     

     

  • 300.00 lei

    Se tipărește la comandă în aproximativ 4-8 săptămâni.

    The single most important fact about breast cancer is the great variation in its natural history and its responsiveness to therapy from one patient to another. The clinician must integrate an assessment of the patient's likely course based on clinical and pathological staging and laboratory studies with objective evidence on the benefits of therapy. The primary aim of this book is to provide the clinician with the tools to do just that. Outcomes of clinical trials and details about commonly used drug regimens, drug dosage, and the expected side effects are summarized in generous tables and figures. Medical terminology has been defined and descriptions of the evolution in our thinking and understanding of the disease are often given to provide perspective in the interpretation of evidence from current studies for busy clinicians and trainees alike.

  • Manual of Interventional Oncology
    La comanda in aproximativ 4 saptamani
    315.00 lei

    This Manual of Interventional Oncology by Douglas Coldwell is the culmination of more than 30 years of training, hands-on practice, and skills learned from oncology colleagues. The successful practice of interventional oncology (IO) requires familiarity with all cancer interventions, and the ability to recognize each of their strengths and weaknesses. Acquiring basic knowledge of all facets of the vast, ever-evolving cancer treatment paradigm enables greater understanding of how IO fits into the broad cancer management continuum.

    The first five chapters lay a solid foundation, detailing essentials of medical and surgical oncology and radiation, followed by interventional radiology cancer treatments and agents used in cancer chemotherapy. Twelve cancer-specific chapters cover tumor management and discussion of minimally invasive, imageguided tumor ablation techniques for each type of cancer, as well as IO for pain management and palliative care.

    Key Highlights

    • IO interventions for prevalent cancers such as colorectal, pancreatic, prostate, liver, bladder, breast, lung, and gynecologic - and less common pathologies including neuroendocrine tumors of the gastrointestinal tract and cholangiocarcinoma
    • More than 125 illustrations accompany succinct discussions of pathology, epidemiology, genetics, staging, treatment, outcomes, and IO options for each type of tumor
    • An overview of clinical trials provides a glimpse of future IO innovations
    • A road map to a successful IO career includes pearls gleaned from years of managing a thriving practice

    This definitive guide is a must-have for clinicians working in the field of vascular and interventional radiology. It provides interventional radiologists with the necessary building blocks, information, and techniques to thrive in this rapidly evolving specialty.

  • 40000lei 325.00 lei

    TIPARIRE DOAR LA COMANDA!


    Description:

    This issue of Surgical Oncology Clinics of North America is devoted to "Breast Cancer" and is edited by Lisa Newman, MD, of the University of Michigan.  Expert authors in this issue review this topic in articles such as: Applications for Breast MRI; Lobular Neoplasia; Epidemiology of Breast Cancer; Percutaneous Ablation of Breast Tumors; Triple Negative Breast Cancer and the Basal Breast Cancer Subtype; Molecular Profiling of Breast Cancer; Surgical Leadership and Standardization of Multidisciplinary Breast Cancer Care; Neoadjuvant/Primary Systemic Therapy for Breast Cancer; Management of the Clinically Node-Negative Axilla in Patients with Primary and Locally-Recurrent Breast Cancer; Management of the Axilla in Patients with Node-Positive Breast Cancer; Prophylactic Bilateral Mastectomy and Contralateral Prophylactic Mastectomy; Advances in Reconstruction of Mastectomy and Lumpectomy Defects; Nipple-Sparing Mastectomy; and Breast Cancer Disparities.

     

    Tabel of contents:

     

    ·  Foreword: Breast Cancer

    ·  Preface: Breast Cancer

    ·  Epidemiology of Breast Cancer

    ·  Key points

    ·  Introduction

    ·  Incidence, prevalence, and mortality

    ·  Risk factors

    ·  History of benign breast disease

    ·  Lifestyle and dietary

    ·  Radiation exposure

    ·  Summary

    ·  Prophylactic Bilateral Mastectomy and Contralateral Prophylactic Mastectomy

    ·  Key points

    ·  Introduction

    ·  Risk assessment

    ·  Epidemiology and decision making

    ·  Operative technique

    ·  Sequelae of prophylactic mastectomy

    ·  Cost-effectiveness of prophylactic mastectomy

    ·  Summary

    ·  Applications for Breast Magnetic Resonance Imaging

    ·  Key points

    ·  Introduction

    ·  MRI for screening

    ·  MRI for treatment selection

    ·  MRI for occult breast cancer

    ·  MRI to select patients for APBI

    ·  MRI-NAC

    ·  Summary

    ·  Molecular Profiling of Breast Cancer

    ·  Key points

    ·  Molecular profiling of intrinsic subtypes of breast cancer

    ·  Molecular prediction and prognostication for treatment decision making

    ·  Impact of molecular profiling on practice patterns

    ·  Summary

    ·  Management of the Clinically Node-Negative Axilla in Primary and Locally Recurrent Breast Cancer

    ·  Key points

    ·  Introduction

    ·  Sentinel lymph node biopsy in clinically node-negative primary breast cancer

    ·  Management of the clinically node-negative axilla in locally recurrent breast cancer

    ·  Summary

    ·  Management of Axillary Disease

    ·  Key points

    ·  Introduction

    ·  Staging of axillary nodal region

    ·  Clinically node-negative patient

    ·  Clinically node-positive patients

    ·  Ongoing and upcoming clinical trials addressing axillary disease management

    ·  Adjuvant radiation therapy

    ·  Summary

    ·  Lobular Neoplasia

    ·  Key points

    ·  Introduction

    ·  Anatomic pathology and classification

    ·  Molecular features and pathophysiology

    ·  Epidemiology and clinical features

    ·  Clinical management

    ·  Neoadjuvant Therapy in the Treatment of Breast Cancer

    ·  Key points

    ·  Introduction

    ·  Rationale for neoadjuvant chemotherapy

    ·  Comparison of neoadjuvant to adjuvant systemic therapy

    ·  Prognostic significance of tumor response

    ·  Monitoring of response to neoadjuvant therapy

    ·  Impact of neoadjuvant chemotherapy on local-regional therapies

    ·  Summary

    ·  Advances in Breast Reconstruction of Mastectomy and Lumpectomy Defects

    ·  Key points

    ·  Introduction

    ·  Reconstruction of mastectomy defects

    ·  Reconstruction of lumpectomy defects

    ·  Technological aids in breast reconstruction

    ·  Possible directions in the future

    ·  Supplementary data

    ·  Nipple-Sparing Mastectomy

    ·  Key points

    ·  Historical perspective

    ·  Birth of breast reconstruction and subcutaneous mastectomy

    ·  Cosmetic importance of the nipple-areola complex

    ·  Autologous tissue flap reconstruction and skin-sparing mastectomy

    ·  Nipple areolar preservation or reconstruction

    ·  Birth of the areola-sparing mastectomy

    ·  Rebirth of the nipple-sparing mastectomy

    ·  Technical development

    ·  Timeline

    ·  Long-term outcomes data

    ·  Lessons learned

    ·  Lessons to be learned: impact on body image and quality of life

    ·  Summary

    ·  Supplementary data

    ·  Basal-Like and Triple-Negative Breast Cancers

    ·  Key points

    ·  Introduction

    ·  Clinical and histopathologic features

    ·  Epidemiology and risk factors

    ·  Targeted therapies

    ·  Summary

    ·  Breast Cancer Disparities

    ·  Key points

    ·  Introduction

    ·  Disentangling socioeconomic resources from racial-ethnic identity in explaining breast cancer disparities

    ·  Epidemiology and risk factors for breast cancer associated with African ancestry

    ·  Breast cancer in African American women: implications for screening mammography recommendations

    ·  Breast cancer risk assessment and chemoprevention in African American women

    ·  BRCA genetic testing, hereditary susceptibility, and African ancestry

    ·  Summary

    ·  Nonsurgical Ablation of Breast Cancer

    ·  Key points

    ·  Introduction

    ·  Clinical outcomes

    ·  Radiofrequency ablation

    ·  Cryoablation

    ·  High-intensity focused ultrasonography

    ·  Microwave thermotherapy

    ·  Novel technologies

    ·  Concerns for the future

    ·  Summary

    ·  Surgical Leadership and Standardization of Multidisciplinary Breast Cancer Care

    ·  Key points

    ·  History of multidisciplinary care

    ·  Standardization of the multidisciplinary breast cancer care

    ·  The national accreditation program for breast centers

  • 37500lei 338.00 lei

    Clinicians and scientists are increasingly recognising the importance of an evolutionary perspective in studying the aetiology, prevention, and treatment of human disease; the growing prominence of genetics in medicine is further adding to the interest in evolutionary medicine. In spite of this, too few medical students or residents study evolution. This book builds a compelling case for integrating evolutionary biology into undergraduate and postgraduate medical education, as well as its intrinsic value to medicine. Chapter by chapter, the authors - experts in anthropology, biology, ecology, physiology, public health, and various disciplines of medicine - present the rationale for clinically-relevant evolutionary thinking. They achieve this within the broader context of medicine but through the focused lens of maternal and child health, with an emphasis on female reproduction and the early-life biochemical, immunological, and microbial responses influenced by evolution. The tightly woven and accessible narrative illustrates how a medical education that considers evolved traits can deepen our understanding of the complexities of the human body, variability in health, susceptibility to disease, and ultimately help guide treatment, prevention, and public health policy. However, integrating evolutionary biology into medical education continues to face several roadblocks. The medical curriculum is already replete with complex subjects and a long period of training. The addition of an evolutionary perspective to this curriculum would certainly seem daunting, and many medical educators express concern over potential controversy if evolution is introduced into the curriculum of their schools. Medical education urgently needs strategies and teaching aids to lower the barriers to incorporating evolution into medical training. In summary, this call to arms makes a strong case for incorporating evolutionary thinking early in medical training to help guide the types of critical questions physicians ask, or should be asking. It will be of relevance and use to evolutionary biologists, physicians, medical students, and biomedical research scientists.

  • 43000lei 345.00 lei

     Carte tiparita la comanda!



    Proposed topics for this issue include: Overview of Colorectal Cancer Genetics; Familial Adenomatous Polyposis; MYH Associated Polyposis; Other genetic colorectal cancer syndromes; Hereditary Nonpolyposis Colorectal Cancer – emphasis on MSH2/MLH1; Hereditary Nonpolyposis Colorectal Cancer – emphasis on PMS2/MSH6; Familial Colorectal Cancer Syndrome Type X; Genome Wide Association Studies and Colorectal Cancer Risk; Genetic Counseling for Hereditary Colorectal Cancer; Genetic Testing for Hereditary Colorectal Cancer; Role of surgery in HNPCC and FAP.

  • 40000lei 345.00 lei

    Carte tiparita la comanda!

    Description:

    This issue of Surgical Oncology Clinics of North America, edited by Dr. Lawrence Wagman, is devoted to Hepatocellular Cancer, Cholangiocarcinoma, and Metastatic Tumors of the Liver. Articles in this issue include: Epidemiology of Hepatomas; Risk Modeling: disease prevalence, outcome from treatment; Imaging; Resection techniques; Ablation techniques; Complications of interventions; Trans-arterial chemo-embolization (TACE); Continuous hepatic artery infusion (CHAI); Selective interstitial radiation therapy (SIRT) and External beam radiation therapy (EBRT); Systemic chemotherapy of HCC and Cholangiocarcinoma; and Systemic chemotherapy and CRC metastases.

     Table of Contents:

    ·  Contributors

    ·  Consulting Editor

    ·  Editor

    ·  Authors

    ·  Forthcoming Issues

    ·  Forthcoming Issues

    ·  Recent Issues

    ·  Foreword: Hepatocellular Cancer, Cholangiocarcinoma, and Metastatic Tumors of the Liver

    ·  Preface: Hepatocellular Cancer, Cholangiocarcinoma, and Metastatic Tumors of the Liver

    ·  Epidemiology of Hepatocellular Carcinoma

    ·  Key points

    ·  Introduction

    ·  Incidence

    ·  Risk factors

    ·  Patient factors

    ·  Economic/public health aspect

    ·  Summary

    ·  Imaging Approach to Hepatocellular Carcinoma, Cholangiocarcinoma, and Metastatic Colorectal Cancer

    ·  Key points

    ·  Introduction

    ·  Liver imaging modalities

    ·  Imaging liver lesions

    ·  Summary

    ·  Prognostication Systems as Applied to Primary and Metastatic Hepatic Malignancies

    ·  Key points

    ·  Introduction

    ·  Primary hepatic malignancies

    ·  Hepatic colorectal adenocarcinoma metastases

    ·  Summary

    ·  Modern Technical Approaches in Resectional Hepatic Surgery

    ·  Key points

    ·  Introduction

    ·  Indications for liver resection

    ·  Preoperative functional evaluation

    ·  Anatomy and terminology of liver resection

    ·  Technical considerations and outcomes after liver surgery

    ·  Positioning and setup

    ·  Incisions and retraction

    ·  Intraoperative ultrasonography

    ·  Hepatic mobilization

    ·  Approach to inflow control

    ·  Approach to outflow control

    ·  Techniques of parenchymal transection

    ·  Specific procedures

    ·  Complications Following Hepatectomy

    ·  Key points

    ·  Post-hepatectomy hemorrhage

    ·  Post-hepatectomy venous thrombosis/thromboembolism

    ·  Post-hepatectomy portal vein and hepatic artery thrombosis

    ·  Bile leak

    ·  Post-hepatectomy liver failure

    ·  Summary

    ·  Ablative Technologies for Hepatocellular, Cholangiocarcinoma, and Metastatic Colorectal Cancer of the Liver

    ·  Key points

    ·  Introduction

    ·  Ablation technologies

    ·  Patient selection

    ·  Ablation approaches

    ·  Perioperative process

    ·  Outcomes

    ·  Hepatic Artery Infusion Chemotherapy for Liver Malignancy

    ·  Key points

    ·  Introduction

    ·  Technical aspects

    ·  Management of variant hepatic arterial anatomy

    ·  Postoperative management and treatment surveillance

    ·  Complications

    ·  Clinical outcomes with hepatic artery infusion chemotherapy

    ·  Unresectable colorectal cancer metastases

    ·  Hepatic artery infusion chemotherapy and primary liver tumors

    ·  Hepatic artery infusion chemotherapy and noncolorectal liver metastases

    ·  Summary

    ·  Transarterial Chemoembolization for Primary Liver Malignancies and Colorectal Liver Metastasis

    ·  Key points

    ·  Introduction

    ·  Principles of transarterial chemoembolization

    ·  Hepatocellular carcinoma

    ·  Intrahepatic cholangiocarcinoma

    ·  Metastatic colorectal carcinoma to the liver

    ·  Summary

    ·  Y90 Selective Internal Radiation Therapy

    ·  Key points

    ·  Introduction

    ·  Outcomes

    ·  Complications

    ·  Summary

    ·  Systemic Therapy for Hepatocellular Carcinoma and Cholangiocarcinoma

    ·  Key points

    ·  Scope of the problem

    ·  Hepatocellular carcinoma

    ·  Sorafenib

    ·  Challenges with treatment

    ·  Failure of clinical trials

    ·  Liver-directed therapy and sorafenib

    ·  Cholangiocarcinoma

    ·  Summary

    ·  Integrating Systemic and Surgical Approaches to Treating Metastatic Colorectal Cancer

    ·  Key points

    ·  Introduction

    ·  Systemic regimens for metastatic colorectal cancer

    ·  Maintenance regimens

    ·  Potentially curable advanced colorectal cancer

    ·  Role for resection of primary tumor

    ·  Summary and future directions

  • 350.00 lei

    For more than 30 years, Skeel’s Handbook of Cancer Therapy (formerly Handbook of Cancer Chemotherapy) has been the resource of choice for current, reliable information on cancer treatment for most adults. The 9th Edition reflects recent significant advances in the systemic treatment of cancer, including innovations in immunotherapy, oncology genomics, and molecular targeted therapy. An invaluable reference for all levels of physicians, nurses, and allied health professionals who provide care to cancer patients, this bestselling guide combines the most current rationale and the details necessary to safely administer pharmacologic therapy, offering a balanced synthesis between science and clinical practice. · A new chapter on the Biologic Basis of Molecular Targeted Therapy, as well as a state-of-the-art review of the current development and use of novel immunotherapeutics, bring you up to date with the rationale and use of these newer agents in cancer treatment. · Completely updated throughout to reflect current best practices, including primary indications, usual dosage and schedule, special precautions, and expected toxicities for dozens of new drugs and biologic agents. · New contributors provide a fresh perspective on timely topics in cancer treatment and care. · An updated section on supportive care reflects this essential aspect of the oncology team’s focus. · Regularly updated Inkling content keeps you current with drug profiles and new immunotherapy advances. Now with the print edition, enjoy the bundled interactive eBook edition, which can be downloaded to your tablet and smartphone or accessed online and includes features like: · Complete content with enhanced navigation · Powerful search tools and smart navigation cross-links that pull results from content in the book, your notes, and even the web · Cross-linked pages, references, and more for easy navigation · Highlighting tool for easier reference of key content throughout the text · Ability to take and share notes with friends and colleagues · Quick reference tabbing to save your favorite content for future use

  • 40000lei 358.00 lei

    Carte tiparita la comanda!


    Description:

    This issue of Surgical Oncology Clinics of North America, edited by Dr. John Ridge, is devoted to Head and Neck Cancer.Articles in this issue include: Epidemiology of Head and Neck Cancer; Molecular Biology and Immunology; Examination of the patient with Head and Neck Cancer; Imaging of Head and Neck Cancer; Principles of Radiation Treatment; Principles of Chemotherapy; Principles and Practice of Reconstructive Surgery; Oral Cavity; Oropharynx; Unknown primary; Larynx and Hypopharynx; Nasopharynx; Nose and Sinus; Head and Neck Skin Cancer; and Tumors of the major Salivary Glands.

     

     Table of Contents:

    ·  Copyright

    ·  Contributors

    ·  Consulting Editor

    ·  Editor

    ·  Authors

    ·  Forthcoming Issues

    ·  Forthcoming Issues

    ·  Recent Issues

    ·  Foreword: A Long Overdue Discussion of Head and Neck Cancer

    ·  Preface: Why “Head and Neck Cancer”?

    ·  Epidemiology of Head and Neck Cancer

    ·  Key points

    ·  Introduction

    ·  Risk factors for head and neck cancer

    ·  Trends in head and neck cancer incidence

    ·  Prognosis

    ·  Summary

    ·  Molecular Biology and Immunology of Head and Neck Cancer

    ·  Key points

    ·  Distinct etiologic subsets of head and neck squamous cell carcinoma

    ·  Genetic alterations

    ·  Major pathways

    ·  Examination of the Patient with Head and Neck Cancer

    ·  Key points

    ·  History taking in the head and neck

    ·  Overall function

    ·  Physical examination

    ·  Special considerations by anatomic site

    ·  Summary

    ·  Radiation Treatment of Head and Neck Cancer

    ·  Key points

    ·  Introduction

    ·  Technical principles of modern head and neck radiation therapy

    ·  Clinical evidence in support of highly conformal therapy

    ·  Results of induction and concurrent chemoradiation

    ·  Uniquely evolving issues in oropharyngeal carcinoma

    ·  Posttreatment surveillance

    ·  Postradiation resection

    ·  Sequencing of other therapies around surgery

    ·  Future advances in radiation therapy

    ·  Summary

    ·  Systemic Therapy for Squamous Cell Carcinoma of the Head and Neck

    ·  Key points

    ·  Systemic therapy for localized disease

    ·  Postoperative chemoradiation for squamous cell cancer of the head and neck

    ·  Palliative systemic therapy for recurrent and metastatic disease

    ·  Current investigational approaches

    ·  Summary

    ·  Imaging for Head and Neck Cancer

    ·  Key points

    ·  Head and neck cancer

    ·  Rationale for modality selection

    ·  Diagnostic imaging technique

    ·  Interpretation/assessment of clinical images

    ·  Summary

    ·  Principles and Practice of Reconstructive Surgery for Head and Neck Cancer

    ·  Key points

    ·  Patient evaluation overview

    ·  Soft tissue reconstruction

    ·  Maxilla reconstruction

    ·  Tongue reconstruction

    ·  Mandible reconstruction

    ·  Pharyngeal reconstruction

    ·  Summary

    ·  Cancer of the Oral Cavity

    ·  Key points

    ·  Introduction

    ·  Anatomy of the oral cavity

    ·  Epidemiology and etiology

    ·  Pathology

    ·  Clinical presentation and evaluation

    ·  Treatment

    ·  Outcomes of treatment

    ·  Summary

    ·  Cancer of the Oropharynx

    ·  Key points

    ·  Introduction

    ·  Pathogenesis and prognosis for oropharyngeal malignancies

    ·  Risk-adapted treatment strategies for oropharyngeal squamous cell carcinoma

    ·  Summary

    ·  Treatment/Comparative Therapeutics

    ·  Key points

    ·  Introduction

    ·  Patient evaluation overview

    ·  General principles of therapy

    ·  Radiation therapy in early stage disease

    ·  Combination therapies

    ·  Surgical treatment options

    ·  Treatment resistance and recurrence

    ·  Evaluation of outcome and long-term recommendations

    ·  Summary/discussion

    ·  Nasopharyngeal Carcinoma

    ·  Key points

    ·  Introduction

    ·  Patient evaluation overview

    ·  Primary therapy

    ·  Combination therapies

    ·  Local recurrence/resistance

    ·  Evaluation of outcome and long-term recommendations

    ·  Summary

    ·  Cancers of the Nose, Sinus, and Skull Base

    ·  Key points

    ·  Introduction

    ·  Risk factors

    ·  Anatomy of the nose and sinus

    ·  Anatomy of the anterior skull base

    ·  Sinonasal carcinomas

    ·  Management

    ·  Approaches

    ·  Role of radiation

    ·  Role of chemotherapy

    ·  Summary

    ·  Evaluation and Management of Head and Neck Squamous Cell Carcinoma of Unknown Primary

    ·  Key points

    ·  Introduction

    ·  Patient evaluation

    ·  Initial treatment

    ·  Summary

    ·  Cutaneous Malignancy of the Head and Neck

    ·  Key points

    ·  Introduction

    ·  Epidemiology

    ·  Risk factors

    ·  Nonmelanoma skin cancer

    ·  Melanoma

    ·  Summary

    ·  Cancers of Major Salivary Glands

    ·  Key points

    ·  Histologic classification and staging

    ·  Presentation and work-up

    ·  Selected histologic subtypes of major salivary gland malignancies

    ·  Treatment

  • Perry's The Chemotherapy Source Book
    La comanda in aproximativ 4 saptamani
    45000lei 360.00 lei

    Carte tiparita la comanda!



    Perry’s The Chemotherapy Source Book, now in its fifth edition, provides information on the choice of chemotherapeutic agents, the use of combination chemotherapy, and the toxicity of individual drugs. Organized by site, this is the only book of its kind to focus strictly on the clinical practice of chemotherapy, and is meant to serve as a “one-stop shop” for information on choice of chemotherapeutic agents, treatment outlines, grading of side effects, and dose modification.

  • 37300lei 360.00 lei

    Se tipareste la comanda!


    Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells from patient referral to post-therapy management in a concise and practical format. Providing clinical guidance on the implementation and management of CAR T-cell therapy, this clinical resource keeps you up-to-date on the latest developments in this rapidly evolving area. Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.

  • 43300lei 380.00 lei

    Updated with details on the newest therapies and sporting a new full-color design, this latest edition of Radiation Oncology: Management Decisions continues to offer comprehensive guidance for residents as well as radiation oncologists already in professional practice. You?ll discover the latest treatment plans for numerous cancer sites and tumor types, including the mouth and sinus, gastrointestinal areas, lungs, bones, and blood. Concise, easy-to-read material you can use in a clinical setting immediately with patients! ? Combines comprehensive overviews of basic concepts with the latest radiologic treatment regimens for a wide variety of tumor types and cancer sites. ? Now in full color! Bursting with hundreds of illustrations, figures, and images to illuminate visually important and state-of-the-art techniques. ? Heavily bulleted content format and to-the-point writing style makes content easy to digest and use with patients quickly. ? Chapters that address tumor- or site-specific treatments cover screening, assessment, staging, therapeutic developments, and other key information. ? Features an up-to-date list of commonly prescribed drugs?streamlined for easier reading?and coverage of the latest pain management and palliative treatments. Enrich Your eBook Reading Experience with Enhanced Video, Audio and Interactive Capabilities! ? Read directly on your preferred device(s), such as computer, tablet, or smartphone. ? Customize for your language, including right-to-left reading, vertical writing, and enhanced annotation in over 30 languages. ? Easily convert to audiobook, powering your content with natural language text-to-speech. ? Adapt for unique reading needs, supporting learning disabilities, visual/auditory impairments, second-language or literacy challenges, and more.

  • 43300lei 400.00 lei

     

    Recent scientific advances have revolutionized cancer research and practice, creating a body of molecular biology information that is important to research scientists and clinical oncologists alike. Cancer: Principles and Practice of Oncology: Primer of the Molecular Biology of Cancer, 3rd Edition, keeps you up to date with all that’s new in this rapidly changing field.

    Derived from DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology – widely regarded as the definitive clinical reference in oncology – the third edition of this popular Primer provides a single-volume, highly focused reference on every important frontier in the molecular biology of cancer.

    • Compiles the knowledge and experience of leading scientists and clinicians in the field.
    • Provides separate chapters on each of the 18 most common cancer types, with state-of-the-art information on how molecular biology advances are impacting clinical practice.
    • Includes a thorough chapter on genetic counseling and genetic testing to help you navigate the challenges and ethical dilemmas of cancer genetics.
    • Covers key topics such as Hallmarks of Cancer, Precision Medicine in Oncology, Cancer Immunotherapy, Pharmacogenomics, and many more.

    Enrich Your Ebook Reading Experience

    • Read directly on your preferred device(s), such as computer, tablet, or smartphone.
    • Easily convert to audiobook, powering your content with natural language text-to-speech.

    Table of Contents:

    1.    Contributors

    2.    PART I: Principles of Molecular Oncology

    3.    1. The Cancer Genome

    4.    Yardena Samuels, Alberto Bardelli, Yochai Wolf, and Carlos López-Otin

    5.    Introduction

    6.    Cancer Genes and Their Mutations

    7.    Identification of Cancer Genes

    8.    Cancer Gene Discovery by Sequencing Candidate Gene Families

    9.    Mutational Analysis of Exomes Using Sanger Sequencing

    10.  Next-Generation Sequencing and Cancer Genome Analysis

    11.  Whole-Genome Analysis Utilizing Second-Generation Sequencing

    12.  Whole-Exome Analysis Utilizing Second-Generation Sequencing

    13.  Somatic Alteration Classes Detected by Cancer Genome Analysis

    14.  Pathway-Oriented Models of Cancer Genome Analysis

    15.  Passenger and Driver Mutations

    16.  Networks of Cancer Genome Projects

    17.  The Genomic Landscape of Cancers

    18.  Single-Cell Genomics

    19.  Integrative Analysis of Cancer Genomics

    20.  Immunogenomics

    21.  The Cancer Genome and the New Taxonomy of Tumors

    22.  Liquid Biopsies as a Diagnosis Tool

    23.  Clinical Applications of Liquid Biopsies

    24.  Cancer Genomics and Drug Resistance

    25.  Perspectives of Cancer Genome Analysis

    26.  Acknowledgments

    27.  2. Molecular Methods in Cancer

    28.  Larissa V. Furtado, Jay L. Hess, and Bryan L. Betz

    29.  Applications of Molecular Diagnostics in Oncology

    30.  Biomarker Genetics

    31.  Use of Biomarkers in Diagnosis

    32.  Use of Biomarkers in Prognosis

    33.  Use of Biomarkers in Predicting Response to Therapy

    34.  Use of Biomarkers in Therapeutic Disease Monitoring

    35.  Use of Biomarkers in Risk Assessment and Cancer Prevention

    36.  The Clinical Molecular Diagnostics Laboratory: Rules and Regulations

    37.  Specimen Requirements for Molecular Diagnostics

    38.  Molecular Diagnostics Testing Process

    39.  Targeted Mutation Analysis Methods

    40.  Polymerase Chain Reaction

    41.  Real-time Polymerase Chain Reaction

    42.  Reverse-Transcription Polymerase Chain Reaction

    43.  Allele-Specific Polymerase Chain Reaction

    44.  Fragment Analysis

    45.  Sanger Sequencing

    46.  Pyrosequencing

    47.  Methylation Analysis

    48.  Microsatellite Instability Analysis/Assessment of Mismatch Repair Deficiency

    49.  Fluorescence In Situ Hybridization

    50.  Whole-Genome Analysis Methods

    51.  Next-Generation Sequencing

    52.  Genomic Microarrays

    53.  Expression Panels

    54.  Immunohistochemistry for Tumor Biomarkers

    55.  PD-L1

    56.  ALK and ROS1

    57.  BRAFV600E

    58.  Cell-Free DNA Technologies

    59.  3. Hallmarks of Cancer: An Organizing Principle for Cancer Medicine

    60.  Douglas Hanahan and Robert A. Weinberg

    61.  Introduction

    62.  Hallmark Capabilities, In Essence

    63.  Sustaining Proliferative Signaling

    64.  Somatic Mutations Activate Additional Downstream Pathways

    65.  Disruptions of Negative-Feedback Mechanisms that Attenuate Proliferative Signaling

    66.  Excessive Proliferative Signaling Can Trigger Cell Senescence

    67.  Evading Growth Suppressors

    68.  Mechanisms of Contact Inhibition and Its Evasion

    69.  Corruption of the Transforming Growth Factor β Pathway Promotes Malignancy

    70.  Resisting Cell Death

    71.  Autophagy Mediates Both Tumor Cell Survival and Death

    72.  Necrosis Has Proinflammatory and Tumor-Promoting Potential

    73.  Enabling Replicative Immortality

    74.  Reassessing Replicative Senescence

    75.  Delayed Activation of Telomerase May Both Limit and Foster Neoplastic Progression

    76.  Inducing Angiogenesis

    77.  Gradations of the Angiogenic Switch

    78.  Endogenous Angiogenesis Inhibitors Present Natural Barriers to Tumor Angiogenesis

    79.  Pericytes Are Important Components of the Tumor Neovasculature

    80.  A Variety of Bone Marrow–Derived Cells Contribute to Tumor Angiogenesis

    81.  Activating Invasion and Metastasis

    82.  The Epithelial-to-Mesenchymal Transition Program Broadly Regulates Invasion and Metastasis

    83.  Heterotypic Contributions of Stromal Cells to Invasion and Metastasis

    84.  Plasticity in the Invasive Growth Program

    85.  Distinct Forms of Invasion May Underlie Different Cancer Types

    86.  The Daunting Complexity of Metastatic Colonization

    87.  Reprogramming Energy Metabolism

    88.  Evading Immune Destruction

    89.  Two Ubiquitous Characteristics Facilitate the Acquisition of Hallmark Capabilities

    90.  An Enabling Characteristic: Genome Instability and Mutation

    91.  An Enabling Characteristic: Tumor-Promoting Inflammation

    92.  The Constituent Cell Types of the Tumor Microenvironment

    93.  Cancer-Associated Fibroblasts

    94.  Endothelial Cells

    95.  Pericytes

    96.  Immune Inflammatory Cells

    97.  Stem and Progenitor Cells of the Tumor Stroma

    98.  Heterotypic Signaling Orchestrates the Cells of the Tumor Microenvironment

    99.  Coevolution of the Tumor Microenvironment During Carcinogenesis

    100.               Cancer Cells, Cancer Stem Cells, and Intratumoral Heterogeneity

    101.               Therapeutic Targeting of the Hallmarks of Cancer

    102.               Conclusion and a Vision for the Future

    103.               Acknowledgment

    104.               4. Oncogenic Viruses

    105.               Christopher B. Buck, Lee Ratner, and Giovanna Tosato

    106.               Principles of Tumor Virology

    107.               Papillomaviruses

    108.               History

    109.               Tissue Tropism and Gene Functions

    110.               Human Papillomavirus Vaccines

    111.               Oropharyngeal Cancer

    112.               Nonmelanoma Skin Cancer

    113.               Bladder Cancer

    114.               Polyomaviruses

    115.               History

    116.               BK Polyomavirus

    117.               Merkel Cell Polyomavirus

    118.               Other Human Polyomaviruses

    119.               Epstein-Barr Virus

    120.               History

    121.               Epstein-Barr Virus Life Cycle

    122.               Lymphomas

    123.               Carcinomas

    124.               Prevention and Treatment

    125.               Kaposi Sarcoma Herpesvirus

    126.               History and Epidemiology

    127.               Kaposi Sarcoma–Associated Herpesvirus in Kaposi Sarcoma

    128.               Lymphoproliferative Disorders

    129.               Animal and Human Retroviruses

    130.               Human T-Cell Leukemia Virus Epidemiology

    131.               Human T-Cell Leukemia Virus Molecular Biology

    132.               Clinical Characteristics and Treatment of Human T-lymphotropic Virus 1–Associated Malignancies

    133.               Hepatitis Viruses

    134.               Hepatitis B Virus

    135.               Hepatitis C Virus

    136.               Hepatitis Virus Pathogenesis

    137.               Clinical Characteristics and Treatment of Hepatitis Virus–Associated Malignancies

    138.               Conclusion

    139.               5. DNA Repair in Normal and Cancer Cells

    140.               Meredith A. Morgan and Theodore S. Lawrence

    141.               Introduction

    142.               Radiation-Induced DNA Damage

    143.               Cellular Responses to Radiation-Induced DNA Damage

    144.               Cell Cycle Checkpoint Pathways

    145.               DNA Repair

    146.               Metabolism

    147.               Innate Immune Response

    148.               Chromosome Aberrations Result from Faulty DNA Double-Strand Break Repair

    149.               Membrane Signaling

    150.               The Effect of Radiation on Cell Survival

    151.               In Vivo Survival Determination of Normal Tissue Response to Radiation

    152.               In Vivo Determination of Tumor Response to Radiation

    153.               Factors That Affect Radiation Response

    154.               The Fundamental Principles of Radiobiology

    155.               Dose-Rate Effects

    156.               Relative Biologic Effectiveness

    157.               Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

    158.               Cell Cycle

    159.               Tumor Oxygenation

    160.               Immune Response

    161.               Genetic Signatures

    162.               Drugs That Affect Radiation Sensitivity

    163.               Antimetabolites

    164.               Platinums and Temozolomide

    165.               Taxanes

    166.               Molecularly Targeted Agents

    167.               Immunotherapy

    168.               Radiation Protection

    169.               6. Microbiome and Cancer

    170.               Giorgio Trinchieri

    171.               Introduction

    172.               Cancer as a Disease of the Metaorganism

    173.               Bacteria as Cause of Cancer

    174.               Helicobacter pylori and Stomach Cancer

    175.               Colorectal Cancer

    176.               Tumors in Tissues Not Directly Colonized by the Microbiota

    177.               The Microbiota Modulates Cancer-Predisposing Conditions and Comorbidity

    178.               Bacteria as Cancer Drugs

    179.               Microbiota and Drug Metabolism

    180.               Microbiota and Chemotherapy

    181.               Microbiota and Immunotherapy

    182.               Immune Checkpoint Blockers: Anti-CTLA-4

    183.               Immune Checkpoint Blockers: Anti-PD-1/PD-L1

    184.               Looking Forward

    185.               7. Precision Medicine in Oncology

    186.               James H. Doroshow

    187.               Introduction

    188.               Approach to Precision Medicine in Oncology

    189.               Next-Generation DNA Sequencing for Precision Oncology

    190.               Broadening the Spectrum of Molecular Characterization

    191.               Preclinical Models to Inform Precision Oncology

    192.               Role of Molecular Pharmacodynamics and Diagnostics in Precision Oncology

    193.               Human Biospecimens for Molecular Characterization

    194.               Molecular Pharmacodynamics in Precision Oncology

    195.               Predictive Diagnostic Assays

    196.               Precision Oncology Clinical Trials and Trial Designs

    197.               Imaging and Precision Oncology

    198.               Precision Prevention

    199.               Future Prospects

    200.               8. Cancer Immunotherapy

    201.               Jeffrey Weber and Iulia Giuroiu

    202.               Introduction

    203.               Interferon-α

    204.               Interleukin-2

    205.               Talimogene Laherparepvec

    206.               Granulocyte Macrophage Colony-Stimulating Factor

    207.               Tumor-Infiltrating Lymphocytes

    208.               Checkpoint Inhibitors—Cytotoxic T-Lymphocyte Antigen 4 and Programmed Cell Death Protein 1

    209.               Cytotoxic T-Lymphocyte Antigen 4 Blockade

    210.               Programmed Cell Death Protein 1 and Programmed Cell Death Protein Ligand 1 Blockade

    211.               Melanoma

    212.               Non–small-cell Lung Cancer

    213.               Mismatch-Repair Deficient or Microsatellite Instability-High Cancers

    214.               Renal Cell Carcinoma

    215.               Hodgkin Lymphoma

    216.               Head and Neck Squamous Cell Carcinoma

    217.               Urothelial Carcinoma

    218.               Merkel Cell Carcinoma

    219.               Hepatocellular Carcinoma

    220.               Gastric Cancer

    221.               Cervical Cancer

    222.               Primary Mediastinal Large B-Cell Lymphoma

    223.               Dosing

    224.               Vaccines

    225.               Sipuleucel-T

    226.               Conclusion

    227.               9. Immunotherapy Agents

    228.               Jeffrey A. Sosman and Douglas B. Johnson

    229.               Introduction

    230.               Human Tumor Antigens

    231.               Mutanome-Associated Neoantigens

    232.               Tumor Vaccines

    233.               Personalized Neoantigen Vaccination

    234.               Immune Checkpoint Inhibitors

    235.               Other Immune Checkpoint Inhibitors in Development

    236.               Anti-TIGIT

    237.               TIM-3

    238.               LAG-3

    239.               KIR

    240.               CD73

    241.               VISTA

    242.               B7-H3

    243.               Immune Checkpoint Activators

    244.               4-1BB (CD137)

    245.               GITR

    246.               ICOS

    247.               CD40

    248.               CD27-CD70

    249.               OX40

    250.               Oncolytic Viruses

    251.               Talimogene Laherparepvec

    252.               Other Oncolytic Viruses

    253.               Factors to Activate Immune Effector Cells

    254.               Cytokines

    255.               IL-2 Variant Molecules

    256.               Signaling Modulation

    257.               STAT3 Inhibition

    258.               PI3Kδ Inhibitors

    259.               PI3Kγ Inhibitors

    260.               Chemokine Inhibitors

    261.               CXCR2 Inhibitors

    262.               CCR2 Inhibitors

    263.               CXCR4 Inhibitors

    264.               CCR4 Antibodies

    265.               CCR5 Inhibitors

    266.               Soluble Factors

    267.               IDO Inhibition

    268.               Arginase Inhibitor

    269.               TGF-β Kinase Inhibitors

    270.               Adenosine A2α Receptor Axis

    271.               Adenosine Receptor Inhibitors

    272.               Innate Immune Modulation

    273.               Pathogen-Associated Molecular Patterns, Damage-Associated Molecular Patterns, and Pattern Recognition Receptors

    274.               Toll-Like Receptor Modulators

    275.               STING Agonists

    276.               Anti-CD47 Monoclonal Antibodies

    277.               Colony-Stimulating Factor 1 Receptor Inhibition

    278.               Bifunctional Fusion Proteins

    279.               Immunocytokines

    280.               Adoptive Cell Therapy

    281.               Chimeric Antigen Receptor T-Cell Therapy

    282.               10. Monoclonal Antibodies

    283.               Hossein Borghaei, Matthew K. Robinson, Gregory P. Adams, and Louis M. Weiner

    284.               Introduction

    285.               Immunoglobulin Structure

    286.               Structural and Functional Domains

    287.               Modified Antibody-Based Molecules

    288.               Factors Regulating Antibody-Based Tumor Targeting

    289.               Antibody Size

    290.               Tumor Antigens

    291.               Half-Life/Clearance Rate

    292.               Glycosylation

    293.               Unconjugated Antibodies

    294.               Cell-Mediated Cytotoxicity

    295.               Complement-Dependent Cytotoxicity

    296.               Altering Signal Transduction

    297.               Immunoconjugates

    298.               Antibody–Drug Conjugates

    299.               Radioimmunoconjugates

    300.               Antibodies Approved for Use in Solid Tumors

    301.               Trastuzumab

    302.               Pertuzumab

    303.               Cetuximab

    304.               Panitumumab

    305.               Necitumumab

    306.               Bevacizumab

    307.               Ado-Trastuzumab Emtansine

    308.               Ramucirumab

    309.               Denosumab

    310.               Antibodies Used in Hematologic Malignancies

    311.               Rituximab

    312.               ofatumumab

    313.               Alemtuzumab

    314.               Brentuximab Vedotin

    315.               Inotuzumab Ozogamicin

    316.               Obinutuzumab

    317.               Blinatumomab

    318.               Daratumumab

    319.               Elotuzumab

    320.               Dinutuximab

    321.               Olaratumab

    322.               Conclusion

    323.               11. Cancer Susceptibility Syndromes

    324.               Alice Hawley Berger and Pier Paolo Pandolfi

    325.               Introduction

    326.               Principles of Cancer Susceptibility

    327.               The “Two-Hit” Paradigm

    328.               What Is the Function of a Tumor Suppressor?

    329.               Haploinsufficiency and Compound Haploinsufficiency

    330.               Genetic Testing

    331.               Cancer Susceptibility Syndromes

    332.               Retinoblastoma

    333.               Incidence

    334.               Genetic Basis

    335.               Molecular Mechanism

    336.               Mouse Models

    337.               Clinical Features and Therapeutic Intervention

    338.               Most Prevalent Syndromes

    339.               Lynch Syndrome

    340.               Hereditary Breast and Ovarian Cancer

    341.               Neurofibromatosis Type 1

    342.               Familial Adenomatous Polyposis

    343.               Other Syndromes, by Function

    344.               Genomic Integrity and Apoptosis

    345.               Regulation of Protein Translation

    346.               Proliferation

    347.               Angiogenesis

    348.               Principles of Cancer Chemoprevention

    349.               Emerging Knowledge and New Lessons

    350.               Germline Mutations in Sporadic Cancer

    351.               Weak Modifiers

    352.               Epigenetic Factors

    353.               Role of Noncoding RNAs

    354.               The Regulatory Genome

    355.               High-Throughput Methods for Understanding Cancer Variants

    356.               Conclusion

    357.               12. Pharmacogenomics

    358.               Christine M. Walko and Howard L. McLeod

    359.               Introduction

    360.               Pharmacogenomics of Tumor Response

    361.               Pathway-Directed Anticancer Therapy

    362.               Genetic-Guided Therapy: Practical Issues in Somatic Analysis

    363.               Pharmacogenomics of Chemotherapy Drug Toxicity

    364.               Thiopurine Methyltransferase

    365.               Dihydropyrimidine Dehydrogenase

    366.               Conclusions and Future Directions

    367.               13. Genetic Counseling

    368.               Danielle C. Bonadies, Meagan B. Farmer, and Ellen T. Matloff

    369.               Introduction

    370.               Who is a Candidate for Cancer Genetic Counseling?

    371.               Components of the Cancer Genetic Counseling Session

    372.               Precounseling Information

    373.               Family History

    374.               Dysmorphology Screening

    375.               Risk Assessment

    376.               Genetic Testing

    377.               Options for Surveillance, Risk Reduction, and Tailored Treatment

    378.               Follow-up

    379.               Issues in Cancer Genetic Counseling

    380.               Genetic Test Selection and Approaches

    381.               Management of the Patient with a Pathogenic Variant in a Moderate-Risk or Lesser Known Gene

    382.               Genetic Testing in Children

    383.               Reproductive Issues

    384.               Potential Germline Implications of Tumor Genomic Profiling

    385.               Changes in Delivery Models

    386.               Direct-to-Consumer Genetic Testing

    387.               Psychosocial Issues

    388.               Confidentiality

    389.               Insurance and Discrimination Issues

    390.               Future Directions

    391.               Whole-Genome Sequencing and Whole-Exome Sequencing

    392.               General Population Testing

    393.               CRISPR

    394.               Conclusion

    395.               PART II: Molecular Biology of Individual Cancers

    396.               14. The Molecular Biology of Head and Neck Cancers

    397.               Thomas E. Carey, Mark E. Prince, and J. Chad Brenner

    398.               Incidence, Risk Factors, and Etiology

    399.               Oral Tongue Cancer in Young Patients

    400.               High-Risk Hpv in Oropharyngeal Cancer

    401.               Molecular Mechanisms in Hnscc

    402.               The Cancer Genome Atlas Project

    403.               Inhibition of Hnscc Immune Escape

    404.               Cancer Stem Cells

    405.               15. The Molecular Biology of Lung Cancer

    406.               Jill E. Larsen and John D. Minna

    407.               Introduction

    408.               Genomics: Tools for Identification, Prediction, and Prognosis

    409.               Somatic Landscape of Lung Cancer

    410.               Characterization of Aberrant Pathways

    411.               Transcriptome Profiling

    412.               Proteomic Approaches

    413.               Lessons Learned and Future Directions

    414.               Functional Genomics in Lung Cancer

    415.               Genome-wide RNA-Based and shRNA-Based Screening

    416.               CRISPR-Cas9 Gene Editing

    417.               Preclinical Model Systems for Studying Lung Cancer

    418.               Genetic and Epigenetic Alterations in Lung Cancer

    419.               EGFR/HER2/MET Signaling

    420.               EGFR

    421.               ERBB2 (HER2)

    422.               MET

    423.               RAS/RAF/MAPK Pathway

    424.               RAS

    425.               RAF

    426.               MEK (MAP2K1 or MEK1)

    427.               MYC

    428.               Pl3K/AKT/mTOR Pathway

    429.               STK11 (LKB1)

    430.               Insulin Growth Factor Pathway

    431.               Fibroblast Growth Factor Pathway

    432.               The p53 Pathway

    433.               The p16INK4a-RB Pathway

    434.               Fusion Proteins

    435.               ALK

    436.               ROS1

    437.               RET

    438.               NTRK

    439.               BRAF

    440.               EGFR

    441.               Epigenetic Changes in Lung Carcinogenesis

    442.               Methylation and Chromatin Remodeling

    443.               Noncoding RNAs

    444.               NFIB, a Metastasis-Inducing Transcription Factor

    445.               KDM Lysine Demethylases (JumonjiC) as an Epigenomic Drug Resistance Mechanism

    446.               Metastasis and the Tumor Microenvironment

    447.               Epithelial-to-Mesenchymal Transition

    448.               Angiogenesis

    449.               Immune Checkpoint Inhibition

    450.               Exosomes as a Source of Information on Tumor Molecular Alterations

    451.               Lung Cancers Stem Cells

    452.               Telomerase-Mediated Cellular Immortality in Lung Cancer

    453.               Clinical Translation of Molecular Data

    454.               Current Translation of Rationale-based Targeted Therapy

    455.               Potential for Future Clinical Translation

    456.               16. Molecular Biology of the Esophagus and Stomach

    457.               Anil K. Rustgi

    458.               Introduction

    459.               Molecular Biology of Esophageal Cancer

    460.               Epidermal Growth Factor Receptor

    461.               Cyclin D1 and p16INK4a

    462.               TP53 Tumor Suppressor Genes

    463.               Telomerase Activation

    464.               Tumor Invasion and Metastasis

    465.               Models of Esophageal Squamous Cell Cancer and Esophageal Adenocarcinoma

    466.               Functional Genomics

    467.               Molecular Biology of Gastric Cancer

    468.               Inherited Susceptibility

    469.               Role of Helicobacter pylori Infection and Other Host–Environmental Factors

    470.               Molecular Genetic Alterations

    471.               Models of Gastric Cancer

    472.               17. The Molecular Biology of Pancreas Cancer

    473.               Scott E. Kern and Ralph H. Hruban

    474.               Introduction

    475.               Common Genetic Changes in Pancreatic Ductal Adenocarcinoma

    476.               Less-Prevalent Genetic Changes in Pancreatic Ductal Adenocarcinoma

    477.               Other Neoplastic Lesions

    478.               18. Molecular Biology of Liver Cancer

    479.               Jens U. Marquardt and Snorri S. Thorgeirsson

    480.               Introduction

    481.               Genetic Alterations in Liver Cancer

    482.               Epigenetic Alterations in Liver Cancer

    483.               Mutational Landscape of Genetic Alterations—The Next Generation

    484.               The Microenvironment of Liver Cancer

    485.               Classification and Prognostic Prediction of Hepatocellular Carcinoma

    486.               Molecular Basis of Cholangiocarcinoma

    487.               Conclusion and Perspective

    488.               19. Molecular Biology of Colorectal Cancer

    489.               Ramesh A. Shivdasani

    490.               Introduction

    491.               Multistep Models of Colorectal Cancer and Genetic Instability

    492.               Mutational and Epigenetic Landscapes in Colorectal Cancer

    493.               Insights from Mouse Intestinal Crypts and Human Colorectal Cancers Lead to a Coherent Model for Colorectal Cancer Initiation and Progression

    494.               WNT Signaling

    495.               Other Growth Factor Pathways

    496.               Inherited Syndromes of Increased Cancer Risk Highlight Early Events and Critical Pathways in Colorectal Tumorigenesis

    497.               Familial Adenomatous Polyposis and the Central Importance of WNT Signaling

    498.               Hereditary Nonpolyposis Colorectal Cancer and the Role of DNA Mismatch Repair

    499.               Other Inherited Syndromes with Elevated Colorectal Cancer Risk

    500.               Familial Juvenile Polyposis

    501.               Insights from Mendelian Syndromes, Genome-Wide Association Studies, and the Microbiome

    502.               Oncogene and Tumor Suppressor Gene Mutations in Colorectal Cancer Progression

    503.               The KRAS, BRAF, and PIK3CA Oncogenes

    504.               MYC, CDK8, and Control of Cell Growth and Metabolism

    505.               TP53 and Other Tumor Suppressors

    506.               Prognostic and Predictive Value of Tumor Genotypes and Molecular Properties

    507.               20. Molecular Biology of Kidney Cancer

    508.               W. Marston Linehan and Laura S. Schmidt

    509.               Introduction

    510.               Clear Cell Renal Cell Carcinoma

    511.               von Hippel-Lindau Disease

    512.               Genetics of von Hippel-Lindau Disease: VHL Gene

    513.               Gene Mutated in Renal Cancer Families with Chromosome 3p Translocations

    514.               Sporadic Clear Cell Kidney Cancer: VHL Gene Mutation

    515.               Function of the von Hippel-Lindau Protein

    516.               Additional Genes Mutated in Clear Cell Kidney Cancer

    517.               Papillary Renal Cell Carcinoma

    518.               Hereditary Papillary Renal Carcinoma: Type 1 Papillary

    519.               Genetics of Hereditary Papillary Renal Carcinoma: MET Protooncogene

    520.               Hereditary Papillary Renal Carcinoma: Functional Consequences of MET Mutations

    521.               Sporadic Type 1 Papillary Renal Cell Carcinoma

    522.               Xp11.2 Translocation Renal Cell Cancer

    523.               Hereditary Leiomyomatosis and Renal Cell Carcinoma: Type 2 Papillary

    524.               Hereditary Leiomyomatosis and Renal Cell Carcinoma: Fumarate Hydratase Gene

    525.               Functional Consequences of Fumarate Hydratase Mutations

    526.               Sporadic Type 2 Papillary Renal Cell Carcinoma

    527.               Chromophobe Renal Cell Carcinoma

    528.               Birt-Hogg-Dubé Syndrome

    529.               Birt-Hogg-Dubé Syndrome: FLCN Gene

    530.               Function of the Birt-Hogg-Dubé Protein: Folliculin

    531.               Sporadic Chromophobe Renal Cell Carcinoma

    532.               Additional Types of Renal Cell Carcinoma

    533.               Tuberous Sclerosis Complex

    534.               Succinate Dehydrogenase–Associated Renal Cancer

    535.               Conclusion

    536.               21. Molecular Biology of Bladder Cancer

    537.               Carolyn D. Hurst and Margaret A. Knowles

    538.               Introduction

    539.               Mutational Landscape

    540.               Mutation Rates, Mutational Signatures, and Mutational Processes

    541.               FGFR3, PIK3CA, and RAS Genes

    542.               Telomerase Reverse Transcriptase Promoter

    543.               TP53, RB1, and CDKN2A

    544.               Genes Involved in Chromatin Modification and Architecture

    545.               STAG2

    546.               Alterations in DNA Repair Pathways

    547.               Structural Alterations to the Genome

    548.               Heterogeneity and Clonal Evolution

    549.               Molecular Subtypes

    550.               DNA-Based Subtypes

    551.               Transcriptome-Based Subtypes

    552.               Therapeutic Opportunities and Future Outlook

    553.               22. The Molecular Biology of Prostate Cancer

    554.               Charles Dai and Nima Sharifi

    555.               Introduction

    556.               The Genomic Landscape of Prostate Cancer

    557.               The Molecular Subtypes of Primary Prostate Cancer

    558.               ETS Family Gene Fusions

    559.               Speckle-Type POZ Protein Mutations

    560.               Forkhead Box A1 Mutations

    561.               Serine Peptidase Inhibitor, Kazal Type 1 Overexpression

    562.               Isocitrate Dehydrogenase 1 Mutations

    563.               The Clonal Evolution of Lethal Metastatic Prostate Cancer

    564.               Genetic Basis of Prostate Cancer Heritability

    565.               Androgen Signaling in Prostate Cancer

    566.               androgen Receptor Structure and Function

    567.               androgen Receptor Action

    568.               Intratumoral androgen Biosynthesis

    569.               Glucocorticoid Signaling in Treatment Resistance

    570.               Other Signaling Pathways in Prostate Cancer

    571.               Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway

    572.               Other Signaling Pathways in Prostate Cancer

    573.               Cell Cycle Aberrations

    574.               Neuroendocrine Prostate Cancer

    575.               Areas of Ongoing Research and Emerging Therapeutic Approaches

    576.               DNA Repair Pathway

    577.               Epigenetic Alterations

    578.               Conclusion

    579.               23. Molecular Biology of Gynecologic Cancers

    580.               Tanja Pejovic, Adam J. Krieg, and Kunle Odunsi

    581.               Introduction

    582.               Ovarian Cancer

    583.               Origins of Epithelial Ovarian Cancer

    584.               Molecular Pathways to Ovarian Cancer

    585.               Inherited Syndromes of Ovarian Cancers

    586.               Targeting Homologous Recombination Defects in Gynecologic Cancer

    587.               Ovarian Cancer Microenvironment, Metastases, and Angiogenesis

    588.               Ovarian Cancer Microenvironment

    589.               Angiogenesis and Tumor Hypoxia

    590.               Influences of the Microenvironment on Tumor Metastasis

    591.               Epigenetics

    592.               Role of Specific Immune Responses and Immunotherapy

    593.               Immune Inhibitory Network and Immune Checkpoint Inhibitors in Ovarian Cancer

    594.               Immunotherapy Clinical Trials in Ovarian Cancer

    595.               Adoptive Cellular Transfer Therapy

    596.               Endometrial Cancer

    597.               Type I Cancers

    598.               Type II Endometrial Cancer

    599.               Microsatellite Instability

    600.               PTEN

    601.               KRAS Mutations

    602.               β-Catenin

    603.               Cervix, Vaginal, and Vulvar Cancers

    604.               Role of Human Papillomavirus

    605.               Immune Evasion by Human Papillomavirus

    606.               Human Papillomavirus Vaccines

    607.               Adoptive T-Cell Therapy

    608.               24. Molecular Biology of Breast Cancer

    609.               Ana T. Nunes, Tara Berman, and Lyndsay Harris

    610.               Introduction

    611.               Genetics of Breast Cancer

    612.               Hereditary Breast Cancer

    613.               High-Penetrance, Low-Frequency Genes

    614.               Moderate-Penetrance, Low-Frequency Genes

    615.               Low-Penetrance, High-Frequency Genes and Loci

    616.               Microsatellite Instability in Breast Cancer

    617.               Somatic Alterations in Breast Cancer

    618.               Copy Number Alterations in Breast Cancer

    619.               Transcriptional Profiles of Breast Cancer—Molecular Subtypes

    620.               Luminal Subtypes

    621.               HER2-Enriched Subtype

    622.               Triple-Negative Subtypes

    623.               Mutational Profiles in Breast Cancer by Molecular Subtype

    624.               Transcriptional Profiles of Breast Cancer—Prognosis and Benefit of Therapy

    625.               70-Gene Assay (Mammaprint)

    626.               21-Gene Recurrence Score (Oncotype DX)

    627.               Prediction Analysis of Microarray-50 (PAM50, PAM50 Risk of Recurrence Score, or Prosigna)

    628.               12-Gene Risk Score (Endopredict)

    629.               Two-Gene Ratio (Breast Cancer Index)

    630.               Epigenetics of Breast Cancer

    631.               Protein/Pathway Alterations

    632.               Estrogen Receptor Pathway

    633.               Growth Factor Receptor Pathways

    634.               Human Epidermal Growth Factor Receptor 2

    635.               RAS and Phosphatidylinositol 3-Kinase Signaling Pathways

    636.               Cyclin-Dependent Kinases

    637.               25. Molecular Biology of Endocrine Tumors

    638.               Zeyad T. Sahli, Brittany A. Avin, and Martha A. Zeiger

    639.               Endocrine Syndromes

    640.               Multiple Endocrine Neoplasia Type 1

    641.               Clinical Features

    642.               Molecular Genetics of MEN1

    643.               Multiple Endocrine Neoplasia Type 2

    644.               Clinical Features of MEN2A

    645.               Clinical Features of MEN2B

    646.               Molecular Genetics of MEN2

    647.               Multiple Endocrine Neoplasia Type 4

    648.               Carney Complex

    649.               Clinical Features

    650.               Molecular Genetics of Carney Complex

    651.               Adrenal Gland

    652.               Cortisol-Producing Adenomas

    653.               Aldosterone-Producing Adenomas

    654.               Pheochromocytoma

    655.               Adrenocortical Carcinoma

    656.               Parathyroid Gland

    657.               Hyperparathyroidism–Jaw Tumor Syndrome

    658.               Familial Hypocalciuric Hypercalcemia

    659.               Neonatal Severe Hyperparathyroidism

    660.               Autosomal Dominant Hypoparathyroidism

    661.               Familial Isolated Hyperparathyroidism

    662.               Pituitary Gland

    663.               Familial Isolated Pituitary Adenoma

    664.               X-linked Acrogigantism

    665.               McCune-Albright Syndrome

    666.               Paraganglioma, Pheochromocytoma, and Pituitary Adenoma Association

    667.               Dicer1 Syndrome

    668.               Thyroid Gland

    669.               Follicular Adenomas

    670.               Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features

    671.               Papillary Thyroid Cancer

    672.               Follicular Thyroid Cancer

    673.               Hürthle Cell Carcinoma

    674.               Medullary Thyroid Cancer

    675.               Anaplastic Thyroid Cancer

    676.               Werner Syndrome

    677.               Acknowledgments

    678.               26. Molecular Biology of Sarcomas

    679.               Samuel Singer and Cristina R. Antonescu

    680.               Introduction

    681.               Soft Tissue Sarcomas

    682.               Translocation-Associated Soft Tissue Sarcomas

    683.               Myxoid/Round Cell Liposarcoma

    684.               Ewing Sarcoma

    685.               Desmoplastic Small Round Cell Tumor

    686.               Synovial Sarcoma

    687.               Alveolar Rhabdomyosarcoma

    688.               Alveolar Soft Part Sarcoma

    689.               Dermatofibrosarcoma Protuberans

    690.               Extraskeletal Myxoid Chondrosarcoma

    691.               Solitary Fibrous Tumor and Hemangiopericytoma

    692.               Soft Tissue Sarcomas of Simple Karyotype Associated With Mutations

    693.               Desmoid Fibromatosis

    694.               Complex Soft Tissue Sarcoma Types

    695.               Well-Differentiated and Dedifferentiated Liposarcoma

    696.               Pleomorphic Liposarcoma

    697.               Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma (Malignant Fibrous Histiocytoma)

    698.               Myxofibrosarcoma

    699.               Undifferentiated Pleomorphic Sarcoma (Malignant Fibrous Histiocytoma)

    700.               Leiomyosarcoma

    701.               Malignant Peripheral Nerve Sheath Tumor

    702.               Angiosarcoma

    703.               Bone and Cartilaginous Tumors

    704.               Cartilaginous Tumors

    705.               Enchondroma

    706.               Osteochondroma

    707.               Chondrosarcoma

    708.               Osteosarcoma

    709.               Future Directions: Next-Generation Sequencing and Functional Screens

    710.               27. Molecular Biology of Cutaneous Melanoma

    711.               Michael A. Davies

    712.               Introduction

    713.               The Cancer Genome Atlas Effort in Cutaneous Melanoma

    714.               The Ras-Raf-Mapk Pathway

    715.               RAF Kinases

    716.               RAS Family GTPases

    717.               NF1

    718.               Additional Oncogenic Pathways

    719.               Cell Cycle Regulators

    720.               The p53 Pathway

    721.               The Phosphatidylinositol 3-Kinase Pathway

    722.               Receptor Tyrosine Kinases

    723.               RAC1

    724.               Telomerase

    725.               Triple Wild-Type Melanomas

    726.               Melanin Synthesis Pathway

    727.               MITF

    728.               The MC1R Pathway

    729.               Summary and Future Directions

    730.               28. Molecular Biology of Central Nervous System Tumors

    731.               Mark W. Youngblood, Jennifer Moliterno Günel, and Murat Günel

    732.               Introduction

    733.               Pediatric Brain Tumors

    734.               Medulloblastoma

    735.               Low-Grade Glioma

    736.               High-Grade Glioma

    737.               Ependymal Tumors

    738.               Adult Brain Tumors

    739.               Low-Grade Glioma

    740.               High-Grade Glioma

    741.               Meningioma

    742.               Summary

    743.               Acknowledgments

    744.               29. Molecular Biology of Lymphoma

    745.               Nicolò Compagno, Laura Pasqualucci, and Riccardo Dalla-Favera

    746.               Introduction

    747.               The Cell of Origin of Lymphoma

    748.               B-Cell Development and the Dynamics of the Germinal Center Reaction

    749.               T-Cell Development

    750.               General Mechanisms of Genetic Alterations in Lymphoma

    751.               Chromosomal Translocations

    752.               Aberrant Somatic Hypermutation

    753.               Copy Number Gains and Amplifications

    754.               Activating Point Mutations

    755.               Inactivating Mutations and Deletions

    756.               Infectious Agents

    757.               Molecular Pathogenesis of B-Cell Non-Hodgkin Lymphoma

    758.               Mantle Cell Lymphoma

    759.               Cell of Origin

    760.               Genetic Lesions

    761.               Burkitt Lymphoma

    762.               Cell of Origin

    763.               Genetic Lesions

    764.               Follicular Lymphoma

    765.               Cell of Origin

    766.               Genetic Lesions

    767.               Diffuse Large B-Cell Lymphoma

    768.               Cell of Origin

    769.               Genetic Lesions

    770.               Primary Mediastinal B-Cell Lymphoma

    771.               Cell of Origin

    772.               Genetic Lesions

    773.               Marginal Zone Lymphoma

    774.               Cell of Origin

    775.               Genetic Lesions

    776.               Chronic Lymphocytic Leukemia

    777.               Cell of Origin

    778.               Genetic Lesions

    779.               Molecular Pathogenesis of T-Cell Non-Hodgkin Lymphoma

    780.               Adult T-Cell Leukemia/Lymphoma (HTLV-1 Positive)

    781.               Cell of Origin

    782.               Genetic Lesions

    783.               Angioimmunoblastic T-Cell Lymphoma

    784.               Cell of Origin

    785.               Genetic Lesions

    786.               Peripheral T-Cell Lymphoma Not Otherwise Specified

    787.               Genetic Lesions

    788.               Cutaneous T-Cell Lymphoma

    789.               Anaplastic Large-Cell Lymphoma

    790.               Cell of Origin

    791.               Genetic Lesions

    792.               Hepatosplenic T-Cell Lymphoma

    793.               Molecular Pathogenesis of Hodgkin Lymphoma

    794.               Cell of Origin

    795.               Genetic Lesions

    796.               30. Molecular Biology of Acute Leukemias

    797.               Glen D. Raffel and Jan Cerny

    798.               Introduction

    799.               Leukemic Stem Cell

    800.               Elucidation of Genetic Events in Acute Leukemia

    801.               Mutations Affecting Transcription Factors

    802.               Core-Binding Factor

    803.               Retinoic Acid Receptor Alpha Gene

    804.               HOX Family Members

    805.               C/EBPα

    806.               GATA Factors

    807.               Mutations that Result in Overexpression of c-MYC

    808.               Mutation of Lymphoid Development Factors in Acute Lymphoid Leukemia

    809.               Chromosomal Translocations Involving the T-cell Receptor

    810.               RBM15/MKL1

    811.               Mutations of Epigenetic Modifiers

    812.               KMT2A (aka MLL) Translocations

    813.               MOZ and TIF2

    814.               TET2

    815.               DNMT3A

    816.               ASXL1

    817.               EZH2

    818.               Mutations Affecting Signaling

    819.               Oncogenic RAS Mutations

    820.               Activating Mutations in Tyrosine Kinases and Associated Receptors

    821.               BCR/ABL1

    822.               FLT3

    823.               KIT

    824.               MPL

    825.               JAK/STAT Pathway

    826.               CRLF2

    827.               Kinases in Ph-Negative Acute Lymphoid Leukemia

    828.               Mutations in Tumor Suppressor Genes

    829.               WT1

    830.               TP53

    831.               Activating Mutations of Notch

    832.               Mutations Altering Localization of Npm1

    833.               Mutations in Cohesin Complex Genes

    834.               Mutations in Splicing Machinery

    835.               Mutational Complementation Groups in Acute Leukemias

    836.               Conclusion

    837.               31. Molecular Biology of Chronic Leukemias

    838.               Christopher A. Eide, James S. Blachly, and Anupriya Agarwal

    839.               Introduction

    840.               Chronic Myeloid Leukemia

    841.               Pathogenesis

    842.               Molecular Anatomy of the BCR-ABL1 Junction

    843.               Functional Domains of BCR-ABL1 and Kinase Activation

    844.               Signal Transduction

    845.               Phosphatidylinositol-3 Kinase

    846.               Rat Sarcoma/Mitogen-Activated Protein Kinase Pathways

    847.               Janus Kinase/Signal Transducer and Activator of Transcription Pathway

    848.               DNA Repair

    849.               Chronic Myeloid Leukemia Stem Cells

    850.               Progression to Blastic Phase

    851.               Chronic Myeloid Leukemia Bone Marrow Microenvironment

    852.               Conclusions

    853.               Chronic Lymphocytic Leukemia

    854.               Origin of Chronic Lymphocytic Leukemia

    855.               Chromosomal Abnormalities in the Pathogenesis of Chronic Lymphocytic Leukemia

    856.               Recurrent Mutations in Chronic Lymphocytic Leukemia

    857.               Progression of Chronic Lymphocytic Leukemia: The Role of Genomic Instability and Clonal Evolution

    858.               Chronic Lymphocytic Leukemia and Proliferation

    859.               Chronic Lymphocytic Leukemia and Disrupted Apoptosis

    860.               B-cell Receptor Signaling in Chronic Lymphocytic Leukemia

    861.               Conclusion

    862.               Acknowledgments

    863.               Index

     

  • Immune Checkpoint Inhibitors in Cancer
    La comanda in aproximativ 4 saptamani
    47800lei 406.00 lei

    Carte tiparita la comanda!




    Description:

    Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It’s an ideal concise reference for trainee and practicing medical oncologists, as well as those in research.

    Features:

    Discusses the current understanding of how to best harness the immune system against different types of cancer at various stages.

    Helps you translate current research and literature into practical information for daily practice.

    Presents information logically organized by disease site.

    Covers tumor immunology and biology; toxicities associated with immune checkpoint inhibitors; and future outlooks.

    Consolidates today’s available information on this timely topic into one convenient resource.

    Table Of Contents:

    1. Tumor Immunology

    2. Melanoma and Other Skin Cancers

    3. Thoracic Malignancies

    4. Gastrointestinal, Hepatobiliary, and Pancreatic Malignancies

    5. Cancers of the Head and Neck

    6. Urologic Malignancies

    7. Gynecologic Malignancies

    8. Breast Cancer

    9. Hematologic Malignancies

    10. Pediatric Malignancies

    11. Toxicities Associated with Immune Checkpoint Inhibitors

    12. Future of Immune Checkpoint Inhibitors

       

    Bottom of Form

     


  • HER2-Positive Breast Cancer
    La comanda in aproximativ 4 saptamani
    47800lei 410.00 lei

    Carte tiparita la comanda!

     

    Description:

    Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.

    Features:

    Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive.

    Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations.

    Includes a timely section on innovative future therapies.

    Table Of Contents:

    Background/testing

    1. The HER2 alteration in breast cancer

    2. HER2 testing in the era of changing guidelines

    Advanced Disease

    3. Optimal first-line treatment of HER2+ advanced disease

    4. Second line therapy and beyond

    5. HER2+ CNS metastases

    Therapeutics

    6. Neoadjuvant therapy

    7. Adjuvant therapy

    8. Outcomes based on HR status in early stage disease

    9. De-escalation of therapy for small tumor

    Toxicity considerations

    10. Cardiac toxicity of HER2-targeted regimens

    11. Non-cardiac toxicity of HER2-targeted therapy

    Therapies on the horizon

    12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc)

    13. Harnessing the immune system in HER2+ disease

    14. Biosimilars

       

     


  • 47800lei 410.00 lei

    Description:

    For those preparing for certification or recertification in hematology or oncologyHoffman and Abeloff's Hematology-Oncology Review is a single-volume source of authoritative, up-to-date exam preparation. This unique question and answer review helps you succeed on today’s board exams with more than 1,000 board-style questions, answers, and rationales; comprehensive coverage of essential exam topics, and online practice tests.

    • Includes 1,000 board-style questions with answers and rationales explaining both correct and incorrect answers.
    • Covers a broad range of topics compiled by experts in hematology and oncology, including cancer biology and genomics, immunotherapy, hematologic malignancies, solid tumor malignancies, non-malignant hematology, and supportive care.
    • Uniquely designed as both a standalone review and a study companion to Abeloff’s Clinical Oncology and Hematology: Basic Principles and Practice.

     

      Table of Contents

    ·  Copyright

    ·  Dedications

    ·  Contributors

    ·  Preface

    ·  Science and Therapy

    ·  Section 1. Cancer Biology, Genomics, and Immunology

    ·  Chapter 1. Cancer Biology

    ·  Chapter 2. Tumor Immunology

    ·  Section 2. Anti-Cancer Therapies

    ·  Chapter 3. Cancer Chemotherapy

    ·  Chapter 4. Immunotherapy and Pathway Inhibitors

    ·  Part 2. Hematologic Malignancies

    ·  Chapter 5. Acute Myeloid Leukemia and Myelodysplastic Syndrome

    ·  Chapter 6. Myeloproliferative Disorders

    ·  Chapter 7. Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, and Other Chronic Lymphoproliferative Disorders

    ·  Chapter 8. Hodgkin Lymphoma

    ·  Chapter 9. Non-Hodgkin Lymphoma

    ·  Chapter 10. Multiple Myeloma and Other Plasma Cell Dyscrasias

    ·  Chapter 11. T-Cell and Natural Killer Cell Neoplasms and Other Lymphoid Malignancies

    ·  Chapter 12. Hematopoietic Cell Transplantation

    ·  Part 3. Solid Tumor Malignancies

    ·  Chapter 13. Breast Cancer

    ·  Early-Stage Breast Cancer

    ·  Metastatic Breast Cancer

    ·  Premalignant Breast Cancer Conditions and In Situ Disease

    ·  Chapter 14. Lung Cancer

    ·  Non-Small Cell Lung Cancer

    ·  Small Cell Lung Cancer

    ·  Chapter 15. Other Thoracic Malignancies

    ·  Mesothelioma

    ·  Thymoma and Thymic Cancer

    ·  Chapter 16. Head and Neck Cancer

    ·  Chapter 17. Esophageal Cancer

    ·  Chapter 18. Gastric Cancer

    ·  Chapter 19. Pancreatic Cancer

    ·  Chapter 20. Colorectal and Anal Cancer

    ·  Chapter 21. Hepatobiliary Cancer

    ·  Chapter 22. Neuroendocrine, Small Bowel, and Appendiceal Malignancies

    ·  Chapter 23. Prostate Cancer

    ·  Chapter 24. Bladder and Other Urothelial Cancers

    ·  Chapter 25. Renal Cell Carcinoma

    ·  Chapter 26. Germ Cell Tumor

    ·  Chapter 27. Gynecological Malignancies

    ·  Ovarian Cancer and Fallopian Tube Cancer

    ·  Cancer of the Cervix, Uterus, Vagina, Vulva, and Gestational Choriorcinoma

    ·  Chapter 28. Melanoma and Other Skin Cancers

    ·  Chapter 29. Bone and Soft Tissue Sarcoma

    ·  Chapter 30. Unknown Primary Site

    ·  Chapter 31. Malignancies of the Central Nervous System

    ·  Primary

    ·  Metastatic

    ·  Chapter 32. Hereditary Cancer Syndromes

    ·  Part 4. Non-Malignant Hematologic Conditions

    ·  Chapter 33. Coagulation

    ·  Chapter 34. Hematopoietic System Disorders

    ·  Chapter 35. Transfusion Medicine

    ·  Part 5. Survivorship and End of Life Care

    ·  Chapter 36. Pain Control and End of Life

  • Pediatric Cancer Genetics
    La comanda in aproximativ 4 saptamani
    44000lei 415.00 lei

    Carte tiparita la comanda!

    Description:

    Get a quick, expert overview of the many key facets of pediatric cancer genetics with this concise, practical resource by Drs. Nathaniel H. Robin and Dr. Nathaniel H. Robin and Meagan Farmer, MS, CGC, MBA. Ideal for pediatric oncologists and all providers who care for children with cancer, this easy-to-read reference addresses the remarkable potential of genetic testing as well as the complexities of choosing the correct test, understanding the results, and counseling the family.

    New To This Edition:

    Features a wealth of information on pediatric cancer genetics, including the epidemiology and biology of cancer and the genetic evaluation process and role of genetic counselors.

    Highlights examples of syndromes that present in childhood and increase susceptibility to cancer.

    Discusses the genetic evaluation process in context of the multidisciplinary care of children with cancer.

    Considers the ethical and legal issues of genetic testing in children and provides illustrative case examples.

    Consolidates today’s available information and guidance in this timely area into one convenient resource.

    Table Of Contents:

    1. Epidemiology of pediatric cancer

    2. The genetics evaluation

    3. Genetic counseling

    4. Cancer biology

    5. Genetic testing techniques

    6. Genetic syndromes associated with cancer predisposition

    7. Ethical and legal issues

    8. Multidisciplinary care of pediatric cancer patients

    9. Case Examples

       

     

    Top of Form

  • 44000lei 420.00 lei

    Get a quick, expert overview of the many key facets of lung cancer evaluation and management with this concise, practical resource by Drs. Lynn T. Tanoue and Frank Detterbeck. This easy-to-read reference presents a summary of today's best evidence-based approaches to diagnosis and management in this critical area.
    Table Of Contents: Diagnosis and Evaluation
    1. The Asymptomatic Patient with a Pulmonary Nodule
    2. Evaluation of the Patient with a Radiographic Abnormality Suspicious for Lung Cancer
    3. Lung Cancer Classification Treatment Considerations
    4. Treatment of Early Stage NSCLC
    5. Curative Intent Treatment of Stage III NSCLC
    6. Advanced NSCLC
    7. Treatment of Small Cell Lung Cancer
    8. Special Types of Lung Cancer
    9. Surveillance and Follow-Up Organization, Quality and Efficiency of Care Delivery
    10. Organization of Lung Cancer Care
    11. Achieving Better Quality of Care Additional Components of Comprehensive Care
    12. Tobacco Use Disorder and Treatment
    13. Healthy Patients at Risk for Lung Cancer: Whether, How and Who to Screen
    14. Symptom Management in Patients with Lung Cancer
    15. Diagnosis and Management of Treatment Related Pulmonary Complications Perspectives
    16. Lung Cancer - Where Are We Now and What is the Future?

  • 47300lei 436.00 lei

    Perfect for radiation oncologists, medical physicists, and residents in both fields, Practical Radiation Oncology Physics provides a concise and practical summary of the current practice standards in therapeutic medical physics. A companion to the fourth edition of Clinical Radiation Oncology, by Drs. Leonard Gunderson and Joel Tepper, this indispensable guide helps you ensure a current, state-of-the art clinical practice. Covers key topics such as relative and in-vivo dosimetry, imaging and clinical imaging, stereotactic body radiation therapy, and brachytherapy. Describes technical aspects and patient-related aspects of current clinical practice. Offers key practice guideline recommendations from professional societies throughout - including AAPM, ASTRO, ABS, ACR, IAEA, and others. Includes therapeutic applications of x-rays, gamma rays, electron and charged particle beams, neutrons, and radiation from sealed radionuclide sources, plus the equipment associated with their production, use, measurement, and evaluation. Features a "For the Physician" box in each chapter, which summarizes the key points with the most impact on the quality and safety of patient care. Provides a user-friendly appendix with annotated compilations of all relevant recommendation documents. Includes an enhanced Expert Consult eBook with open-ended questions, ideal for self-assessment and highlighting key points from each chapter. Download and search all of the text, figures, and references on any mobile device.

  • 56200lei 450.00 lei

    This textbook focuses on the nascent field of Immunoepidemiology that addresses how differences in immune responses among individuals affect the epidemiology of infectious diseases, cancer, hypersensitivity, and autoimmunity. The idea for the book originated from a course entitled “Immunology for Epidemiologists“ at the Yale School of Public Health. While many fine textbooks are available that address the immunological responses of individuals to pathogens, these provided very little information regarding how immunological variation among populations affects the epidemiology of disease. And yet, it has long been recognized that there is great immunologic diversity among people, which can have a profound effect on the epidemiology of disease. Careful review of the immunologic and epidemiologic literature revealed that there have been relatively few publications concerning immunoepidemiology and that no textbook is available on the subject. This textbook therefore aims to fill this void by providing a much-needed tool to comprehensively and efficiently teach immunoepidemiology. The book includes a section on the basic principles of immunology, and then applies them to particular examples of disease in human populations. The target audience for this text book are Masters of Public Health students. Others who should also find it of interest include PhD students in epidemiology, immunology, medical students, generalists, and specialists in immunology, infectious diseases, cancer, and rheumatology.

    ·  Section I. INTRODUCTION

    ·  1. Introduction to Immunology, Epidemiology, and Immunoepidemiology

    ·  Section II. IMMUNOLOGY BASICS

    ·  2. Organization and Cells of the Immune System

    ·  3. Innate Immunity: Recognition and Effector Functions

    ·  4. Adaptive Immunity: Antigen Recognition by T and B Lymphocytes

    ·  5. Adaptive Immunity: Effector Functions, Regulation, and Vaccination

    ·  6. Disorders of the Immune System

    ·  Section III. IMMUNOEPIDEMIOLOGY BASICS: IMMUNOLOGY OF POPULATIONS

    ·  7. Immunoepidemiology of Selected Components of the Innate and Adaptive Immune Systems

    ·  8. Immunoepidemiology of Immune Dysfunction

    ·  Section IV. IMMUNOEPIDEMIOLOGY OF INFECTIOUS DISEASES AND CANCER

    ·  9. Immunoepidemiology of Mycobacterium tuberculosis

    ·  10. Immunoepidemiology of Human Immunodeficiency

    ·  11. Fungal Immunoepidemiology

    ·  12. Immunoepidemiology of Plasmodium falciparum malaria

    ·  13. Immunoepidemiology of Cancer

    ·  Section V. IMMUNOEPIDEMIOLOGIC INVESTIGATIVE, THERAPEUTIC, AND PREVENTATIVE TOOLS

    ·  14. Modeling Approaches Toward Understanding Infectious Disease Transmission

    ·  15. Vaccines

    ·  16. Immunotherapy for Infectious Diseases, Cancer, and Autoimmunity


  • 47300lei 450.00 lei

     

    Offers clear guidance on delivery of modern radiation treatment to gynecological cancers, focusing on external beam planning and brachytherapy

    Covers advanced techniques such as IMRT, IGBT, SBRT, and particle therapy

    Conveys the practical experience of the authors and editors in easy-to-follow methods

     

    About this book

     

    This book is a practical guide to the use of modern radiation therapy techniques in women with gynecological cancers. Step-by-step instruction is provided on simulation, contouring, and treatment planning and delivery for cancers of the cervix, endometrium, vagina, and vulva. Beyond external beam radiation delivery, full details are presented on three-dimensional brachytherapy at all sites for which it is applicable. Moreover, in-depth guidance is offered on the various advanced techniques of radiation delivery, including intensity-modulated radiation therapy, image guidance for external beam and brachytherapy, and stereotactic body radiotherapy.

     

    Radiation therapy is a critical component of the multidisciplinary management of gynecological tumors. With modern technology, both external beam radiation and brachytherapy can be delivered in a highly conformal way. This requires precise contouring and accurate planning techniques. In clearly describing the indications for and the delivery of quality radiation therapy for gynecological tumors, this book will benefit radiation oncologists, medical physicists, medical dosimetrists, radiation therapists, and radiotherapy residents.

     

    Table of contents (10 chapters)

     

    CT and MRI Simulation for Radiation Planning

    Pages 1-22

    Ayala-Peacock, Diandra N. (et al.)

    Anatomy and Target Delineation: Adjuvant and Definitive Radiation Therapy for Cervix Cancer

    Pages 23-41

    Lim, Karen S. H. (et al.)

    Anatomy and Target Delineation: Definitive and Postoperative Adjuvant Radiation Therapy in Uterine Cancer

    Pages 43-61

    Harkenrider, Matthew (et al.)

    Anatomy and Target Delineation: Definitive and Postoperative Adjuvant Radiation Therapy in Vulvar Cancer

    Pages 63-75

    Shen, Colette J. (et al.)

    3D Planning

    Pages 77-106

    Damast, Shari (et al.)

    Intensity-Modulated Radiation Therapy and Volumetric-Modulated Arc Therapy

    Pages 107-139

    Lee Burnett, O., III (et al.)

    Imaging in the Management of Gynecologic Cancers

    Pages 141-164

    Meier, Teresa (et al.)

    Intracavitary Brachytherapy: Definitive, Preoperative, and Adjuvant (Cervix, Uterine, and Vaginal)

    Pages 165-195

    Hasan, Yasmin (et al.)

    Interstitial Brachytherapy - Definitive and Adjuvant

    Pages 197-236

    Dyer, Brandon A. (et al.)

    Stereotactic Ablative Radiotherapy and Other Newer Treatment Delivery Techniques for Gynecologic Cancers

    Pages 237-276

    Feddock, Jonathan (et al.)